Current emerging research shows how gene therapy may be harnessed to block SARM1 and the downstream axon degeneration (66), how SARM1 inhibitors can help restore axons that are in moderate injury prior to full degradation (67), and how Sarm1 ASOs can reduce SARM1 levels and impede axon degeneration (68), thus showing potential for potential use in ADOA therapeutics. The gene discussed is SARM1; the disease is autosomal dominant optic atrophy.